Donald Trump’s proposed 200% tariff on generic drug imports is less a blow to India’s pharmaceutical industry than a costly gamble that could leave American patients paying the highest price.
One side talks about the socialists, the other about the rubes. In both cases, it is often an instance of the same fractious contempt and deep-seated enmity.